Advertisement
Advertisement
U.S. markets open in 2 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
20.42+0.57 (+2.87%)
At close: 04:00PM EDT
20.61 +0.19 (+0.93%)
Pre-Market: 07:00AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close19.85
Open19.95
Bid20.11 x 800
Ask21.20 x 1200
Day's Range19.74 - 21.32
52 Week Range13.84 - 124.79
Volume1,350,242
Avg. Volume1,486,961
Market Cap818.799M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-1.16
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target Est69.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SAVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cassava Sciences, Inc.
    Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study

    Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months of Open-label Treatment with Simufilam Follow: Drug Appears Safe and Well Tolerated.Overall ADAS-Cog11 Scores Improved an Average of 1.5 Points (S.D. ± 6.6; P<0.05)63% of the 100 Patients Showed an Improvement in ADAS-Cog11 Scores, and This Group of Patients Improved an Average of 5.6 Points (S.D. ±

  • InvestorPlace

    10 Stocks to Sell Before They Die

    This article is excerpted from Tom Yeung’s Profit & Protection newsletter dated July 28, 2022. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here. Source: Shutterstock Growing up, my family’s hamburger grilling looked like this. Ground beef? Check.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Salt, pepper and spices? Of course. Then add bell peppers, onions, saltine crackers and an egg for good measure? Umm… That too. It was only after the interne

  • MarketWatch

    Cassava's stock dives 21% after report citing alleged criminal probe of data from Alzheimer's drug trial

    Shares of Cassava Sciences Inc. (sava) plunged 21.0% in trading on Wednesday after Reuters reported that the Justice Department is investigating whether the company manipulated clinical data for a still-investigational Alzheimer's disease drug, citing people familiar with the matter. Cassava put out a news release in December that said a scientific journal did not find evidence of manipulated data in a 2005 paper authored by the company's scientists after short sellers alleged data manipulation in some previously published research. Cassava's Alzheimer's drug candidate is currently in Phase 3 clinical trials.

Advertisement
Advertisement